2.440USD+0.41%Mkt Cap: 73.93M USDP/E: —Last update: 2026-05-26
XBiotech Inc., a biopharmaceutical company, discovers, and develops, True Human monoclonal antibodies for treating various diseases. It develops a pipeline of product candidates targeting inflammatory and infectious dise…
Industry Peers
Biotechnology110.61BUSDP/E 25.8
106.49BDKKP/E 20.5
66.47BUSDP/E 15.5
46.51BEURP/E 30.5
43.17BEURP/E 35.9
39.41BUSDP/E 74.0
32.84BUSD—
31.18BSEKP/E 46.1
Indicators:|
Key Statistics
Company
Market Cap73.93M USD
Enterprise Value-39.85M USD
Revenue (TTM)—
Gross Profit—
Net Income (TTM)-45.54M USD
Revenue/Share—
Last Price2.440 USD
Fiscal Year EndDec 2025
MR QuarterMar 2026
Employees85
CountryUS
SectorHealthcare
IndustryBiotechnology
ISINCA98400H1029
Valuation
P/E (Trailing)—
P/E (Forward)19.08
PEG—
EV/EBITDA0.85
EV/Revenue—
P/S—
P/B0.54
EPS (TTM)-1.31
EPS (Forward)0.13
52W Range
2.09023% of range3.610
52W High3.610 USD
52W Low2.090 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-32.45%
ROA-30.34%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-39.92M USD
CapEx (TTM)289.00K USD
FCF Margin—
FCF Yield-37.15%
Net Debt-115.46M USD
Net Debt/EBITDA2.47
Balance Sheet
Debt/Equity—
Current Ratio39.03
Quick Ratio38.60
Book Value/Sh4.603 USD
Cash/Share3.787 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.0000 USD
Div. Yield—
5Y Avg Yield—
Payout Ratio0.00%
Ex-Div DateJul 15, 2021
Pay DateJul 23, 2021
Analyst Consensus
Rating—
Target (Mean)—
Target Range—
# Analysts—
Ownership
Shares Out.30.49M
Float22.84M
Insiders24.33%
Institutions6.74%
Short Interest
Short Ratio6.8d
Short % Float0.67%
Short % Out.0.57%
Shares Short174.08K
Short (prev mo.)144.18K
Technical
SMA 502.420 (+0.8%)
SMA 2002.547 (-4.2%)
Beta—
S&P 52W Chg28.31%
Avg Vol (30d)25.17K
Avg Vol (10d)26.63K
Technical Indicators
RSI (14)—
MACD—
MACD Signal—
MACD Hist.—
BB Upper—
BB Middle—
BB Lower—
BB Width—
ATR (14)—
Vol Ratio (20d)—